Hospital of Pittsburgh
Dr McKiernan will also join the staff of the hospitalfs Center for Rare Disease Therapy. Dr McKiernan specializes in treating children with inherited metabolic disease and has an interest in developing less invasive therapies to help patients avoid or delay the need for liver transplantation. His research focus covers the clinical aspects of inherited metabolic liver disease, portal hypertension, novel endoscopic techniques, non-invasive markers of hepatic fi brosis, and immunosuppression following liver transplantation. He is actively involved in research on stem cell therapy for metabolic liver diseases and recently was the U.K. principle investigator on a stem cell study involving children with urea cycle disorders and Crigler-Najjar syndrome. "Dr McKiernan is among the worldfs leading physician-scientists with expertise in pediatric hepatology, specifi cally inherited metabolic disease,h said Mark Lowe, M.D., Ph.D., chief of the Division of Pediatric Gastroenterology, Hepatology and Nutrition at Childrenfs Hospital. gHis appointment enhances Childrenfs ability to provide care for children from around the world with complex metabolic conditions in need of the highest level of care."
Dr McKiernan also has a special interest is tyrosinemia, an inherited disorder caused by an enzyme defi ciency that can lead to life-threatening liver and kidney failure. In a study published in 2014, Dr McKiernan and his colleagues found that children whose tyrosinemia was identifi ed at birth through newborn screening and started on the drug nitisinone developed normally and showed no signs of liver or kidney disease.
Dr McKiernan comes to Childrenfs from Birmingham Childrenfs Hospital in the United Kingdom, where he was a hepatologist in the liver unit since 1994. He trained in medicine and pediatrics at Queenfs University in Belfast.
Dr McKiernan is a member of the British Medical Association, British Society of Pediatric Gastroenterology, Hepatology and Nutrition, British Association for the Study of the Liver, and American Association for the Study of Liver Diseases. He also is an associate professor at the University of Pittsburgh School of Medicine.
As an international expert in metabolic disease, Dr McKiernan is part of the Center for Rare Disease Therapy at Childrenfs, an integrated team of experts who have developed innovative therapies to treat a multitude of rare diseases.
Childrenfs has performed more than 330 liver transplants for patients with metabolic disease, which is more than any other center, including adult facilities. In addition, Childrenfs is a leading center for liver transplantation as a therapeutic option for children with maple syrup urine disease (MSUD). Childrenfs developed the fi rst liver transplant protocol for MSUD in 2004 and since then has successfully performed more liver transplants in patients with MSUD than any other center in the world with 100% patient and graft survival.
|Date of upload: 15th Sep 2016|
Copyright © 2016 MiddleEastHealthMag.com. All Rights Reserved.